Evidence map›Paper›PMID 26468984›Full record

ArticleOncotarget2015

Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.

Sripathi M Sureban, Mohammad F Madhoun, Randal May, Dongfeng Qu, Naushad Ali, Javid Fazili, Nathaniel Weygant, Parthasarathy Chandrakesan, Kai Ding, Stanley A Lightfoot and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. DCLK1 autoinhibition and activation in tumorigenesis.Innovation (Cambridge (Mass.)) · 2022
    Article
  9. Pleiotropic effects of DCLK1 in cancer and cancer stem cells.Frontiers in molecular biosciences · 2022
    Review
  10. Review
  11. Structural Basis of Inhibition of DCLK1 by Ruxolitinib.International journal of molecular sciences · 2021
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Sripathi M SurebanDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Mohammad F MadhounDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Randal MayDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Dongfeng QuDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Naushad AliDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Javid FaziliDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Nathaniel WeygantDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Parthasarathy ChandrakesanDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Kai DingDepartment of Biostatistics & Epidemiology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Stanley A LightfootDepartment of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Courtney W HouchenDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
University of Oklahoma Health Sciences Center · USOU Health Stephenson Cancer CenterOklahoma State University Oklahoma City · US

Funding

CSRD VA I01 CX001686
6 · The paper itself

Abstract

Tumor stem cell marker Doublecortin-like kinase1 (DCLK1) is upregulated in several solid tumors. The role of DCLK1 in hepatocellular carcinoma (HCC) is unclear. We immunostained tissues from human livers with HCC, cirrhosis controls (CC), and non-cirrhosis controls (NCC) for DCLK1. Western blot and ELISA analyses for DCLK1 were performed with stored plasma samples. We observed increased immunoreactive DCLK1 in epithelia and stroma in HCC and CCs compared with NCCs, and observed a marked increase in plasma DCLK1 from patients with HCC compared with CC and NCC. Analysis of the Cancer Genome Atlas' HCC dataset revealed that DCLK1 is overexpressed in HCC tumors relative to adjacent normal tissues. High DCLK1-expressing cells had more epithelial-mesenchymal transition (EMT). Various tumor suppressor miRNAs were also downregulated in HCC tumors. We evaluated the effects of DCLK1 knockdown on Huh7.5-derived tumor xenograft growth. This was associated with growth arrest and a marked downregulation of cMYC, and EMT transcription factors ZEB1, ZEB2, SNAIL, and SLUG via let-7a and miR-200 miRNA-dependent mechanisms. Furthermore, upregulation of miR-143/145, a corresponding decrease in pluripotency factors OCT4, NANOG, KLF4, and LIN28, and a reduction of let-7a, miR-143/145, and miR-200-specific luciferase activity was observed. These findings suggest that the detection of elevated plasma DCLK1 may provide a cost-effective, less invasive tool for confirmation of clinical signs of cirrhosis, and a potential companion diagnostic marker for patients with cirrhosis and HCC. Our results support evaluating DCLK1 as a biomarker for detection and as a therapeutic target for eradicating HCC.

Indexed as

Gene Knockdown TechniquesRNAi TherapeuticsAnimalsBiomarkers, TumorCarcinoma, HepatocellularCell Line, TumorCell ProliferationDatabases, GeneticDoublecortin-Like KinasesGene Expression Regulation, NeoplasticGenetic TherapyHumansIntracellular Signaling Peptides and ProteinsKruppel-Like Factor 4Liver CirrhosisLiver NeoplasmsBiomarkers, TumorDCLK1 protein, humanDoublecortin-Like KinasesIntracellular Signaling Peptides and ProteinsKLF4 protein, humanKlf4 protein, mouseKruppel-Like Factor 4MicroRNAsProtein Serine-Threonine KinasesTranscription Factorsbiomarkercirculating DCLK1cirrhosisHCCmiRNA

Identifiers

PMID26468984
PMCPMC4741924
OpenAlexW2239509148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.